Directional atherectomy combined with drug-coated balloon dilatation for femoropopliteal artery diseases: recent advances in research
10.3969/j.issn.1008-794X.2019.03.021
- VernacularTitle:定向斑块旋切联合药物涂层球囊治疗股腘动脉病变进展
- Author:
Zhiwen CAI
1
;
Yongquan GU
Author Information
1. 首都医科大学宣武医院血管外科、血管外科研究所 100053 北京
- Keywords:
femoropopliteal arteriosclerosis obliterans;
directional atherectomy;
drug-coated balloon
- From:
Journal of Interventional Radiology
2019;28(3):301-304
- CountryChina
- Language:Chinese
-
Abstract:
Femoropopliteal arteriosclerosis obliteration has been a common disease affecting human health. Currently, endovascular treatment has become the mainstream of operation, but the postoprative restenosis rate is still very high. Directional atherectomy (DA) can improve blood vessel compliance by removing plaque, but it has no obvious effect in reducing the restenosis rate. The emergence of drug-coated balloon (DCB) has brought the dawn to solve this problem. Through the entry of its loaded drug into the vascular wall to prevent the proliferation of endothelial cells and smooth muscle cells, DCB exerts its long-term anti-intimal hyperplasia effect. A number of studies have shown that DCB can reduce the late lumen loss and the restenosis rate, thus decrease the re-operation rate. Combination use of DA and DCB can improve the uptake of drugs, then, better results can be expected. However, the present research results are not sufficient to support the above theoretical speculation, and large sample and more multicenter randomized controlled studies need to be done before it can be validated.
